Company intelligence / Profile preview

CRISOTH

Austin, Texas, United Statescrisothwelding.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cristcot's lead product, a novel hydrocortisone acetate (HCA) suppository delivered with the Sephure® applicator, achieved positive pivotal Phase 3 results in ulcerative colitis of the rectum—meeting pre-defined outcomes for clinical response by Day 15 and remission by Day 29. The company plans an NDA submission in Q1 2025. The pipeline includes additional GI-focused programs at earlier stages[1][3][4].

Therapeutic areas: Gastroenterology
Modalities: Small moleculeSynthetic glucocorticoid corticosteroidSuppository drug delivery
Industry: Biotech

Beyond the preview

Go deeper on CRISOTH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRISOTH.

Explore the full profile